NIH RePORTER
Cure8 research brief
Multi-target mucosal immunotherapies via engineered biomaterials
Research and clinical trials
Clinical Trial Phase 1
Researchers
Clinicians
Inflammatory bowel disease
Why This Matters
Researchers are trying to create modular mucosal immunotherapies that target both microbial and inflammatory drivers of diseases like colitis. If successful, this approach could lead to treatments that address the combined biology of IBD rather than treating microbial and inflammatory components separately.
Who Should Pay Attention
Researchers in biomaterials, immunology, and IBD; clinician-scientists working on novel IBD therapies; translational researchers interested in mucosal vaccines/immunotherapies.
Study Snapshot
Story typeClinical Reference
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This NIH Reporter project record describes a funded preclinical research program developing modular supramolecular peptide-based mucosal immunotherapies (ISAP) designed to raise neutralizing antibody responses against both microbial virulence factors and inflammatory mediators.
The team plans to: establish design rules for controlling antibody and cellular response kinetics and durability; optimize combined neutralizing responses against selected microbial and inflammatory targets in genitourinary and gastrointestinal mucosa; and test therapeutic efficacy in preclinical models of recurrent UTI and colitis.
The entry is a project-record (funded research) rather than a trial result, so it reports planned aims and preclinical development rather than clinical outcomes. This work is an early-stage translational biomaterials and immunotherapy program aimed at developing integrated, modular approaches to target both microbes and inflammation at mucosal surfaces.
The report focuses on engineering and preclinical evaluation (including murine colitis models) rather than on approved drugs or clinical protocols.
Keep In Mind
This is a funded preclinical project description on NIH Reporter describing planned research (project-record). It does not present clinical trial results or established human treatments. Outcomes will depend on preclinical efficacy and subsequent clinical development.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsJoel H Collier
InstitutionDUKE UNIVERSITY
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedJul 22, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R01AI201850 - $684,405
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease
Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.